Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

CorMedix (CRMD) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for CorMedix (CRMD) over the last 14 years, with Q3 2025 value amounting to 0.01%.

  • CorMedix's EBITDA Margin fell 200.0% to 0.01% in Q3 2025 from the same period last year, while for Sep 2025 it was 8.37%, marking a year-over-year increase of 713400.0%. This contributed to the annual value of 41.25% for FY2024, which is 1351236600.0% down from last year.
  • According to the latest figures from Q3 2025, CorMedix's EBITDA Margin is 0.01%, which was down 200.0% from 0.01% recorded in Q2 2025.
  • In the past 5 years, CorMedix's EBITDA Margin ranged from a high of 192858.54% in Q2 2023 and a low of 100446.94% during Q3 2022
  • Its 5-year average for EBITDA Margin is 1666.4%, with a median of 28.73% in 2024.
  • Per our database at Business Quant, CorMedix's EBITDA Margin surged by 2000000000bps in 2023 and then tumbled by -1928582600bps in 2024.
  • Over the past 5 years, CorMedix's EBITDA Margin (Quarter) stood at 13829.39% in 2021, then crashed by -99bps to 27513.23% in 2022, then soared by 370bps to 74358.67% in 2023, then plummeted by -100bps to 57.44% in 2024, then soared by 100bps to 0.01% in 2025.
  • Its last three reported values are 0.01% in Q3 2025, 0.01% for Q2 2025, and 0.02% during Q1 2025.